ArticleApplied biochemistry and biotechnology2023
Tragia involucrata Leaf-Mediated ZnO NPs: Biomedical Applications, Ointment Formulation and Electrochemical Studies.
Article in Applied biochemistry and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc oxide (ZnO) NPs, owing to their broad biomedical applications, have recently attracted the scientific community with incredible interest as therapeutic agents. So, the present study aims at preparation of ZnO NPs, using Tragia involucrata leaf extract and exploring their capability as antioxidant, anticancer and anti-inflammatory agents. Besides, the ointment formulation and electrochemical studies were also carried out in this work. The antioxidant activity of the synthesized ZnO NPs was evaluated using DPPH assay method and the results clearly showed higher inhibition of about 70% and lower inhibition of about 14% for 100 µg/ml and 25 µg/ml concentrations, respectively. The cytotoxic effects of ZnO NPs were evaluated against human cancer cell lines such as A549 (lungs), HeLa (cervical), HeP-2 (laryngeal) and MCF-7 (breast). The outcome of this investigation confirmed the effectiveness of the synthesized NPs against HeP-2 even at the lowest concentration. The anti-inflammatory activity was measured by the inhibition of protein denaturation assay. A higher inhibition of about 54% was noticed at the concentration of 100 µg/ml. In the case of the ointment formulation study, the pastes prepared using the biosynthesized ZnO NPs and commercially available ZnO powder were compared and evaluated using the parameters such as pH, spreadability, moisture content, extrudability, foamability and physical examinations. As it has been noticed that all the observed parameters were matching well with those of the commercially available ZnO powder, ZnO NPs, synthesized using Tragia involucrata, may be suggested for the clinical trials. Cyclic voltammetry was used to measure the specific capacitance of the synthesized ZnO NPs for different scan rates. The results of this study showed the gradual decrease in specific capacitance value for the corresponding increase in scan rates. Therefore, the results of present study indicated that ZnO NPs prepared using Tragia involucrata leaves were found to be effective for all the above chosen applications and hence, have multifunctional capacity.
Indexed as
Identifiers
35347668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.